After more than a decade of effort to develop RNAi-based therapeutics, everything changed when two RNAi-based drugs received recent FDA approval, opening the door to therapeutic opportunity to discover and develop RNAi based drugs for an abundance of diseases.
The RNAi-Based Therapeutics Summit is the only industry-focused, scientific platform virtually bringing together large pharma, innovative biotech and key opinion leaders of academia dedicated to harnessing the full therapeutic opportunity of upcoming RNAi platforms.
With several clinical candidates emerging and momentum building in the field, digitally join the RNAi-Based Therapeutics Summit - your comprehensive, industry-focused virtual meeting dedicated to bringing together senior biopharmaceutical leaders from discovery, translation, and clinical development functions to advance pioneering RNAi platforms that improve patient outcomes.
Earlybird and group discount rates are available. Visit the website to learn more: https://ter.li/ffybis.
Conference Only: Book By Friday, June 12: USD 1199.0,
Conference Only: Standard Rate: USD 1499.0
Speakers: Brooke Rock, Director, Amgen, Karyn O'Neil, Chief Scientific Officer, Aro Biotherapeutics, Sharmistha Ghosh, Associate Director of CMC Analytical Development, Arrowhead Pharmaceuticals, Jimmy Weterings, Principal Scientist of Chemistry, AstraZeneca, Marc Abrams, Executive Director of Pharmacology, Dicerna Pharmaceuticals, Antonin de Fougerolles, Chief Executive Officer, Evox Therapeutics, David Sharp, Co-Founder and Chief Scientific Officer, MicroCures, Dong-Ki Lee, Founder and Chief Executive Officer, OliX Pharmaceuticals, Elena Feinstein, Chief Scientific Officer, Quark Pharmaceuticals, Basiong Mei, Senior Global Project Head, Sanofi, David Evans, Chief Scientific Officer, Sirnaomics, Anne-Marie Bleau, Clinical Operations Manager, Sylentis, Pavlina Konstantinova, Vice President of Research, uniQure
Time: 9:00 am to 5:30 pm